High-density lipoprotein cholesterol increase in hypertensive patients treated with the calcium channel blocker tiapamil

G. Perani, C. Muggia, A. Martignoni, A. Radaelli, P. Centeleghe, E. Passamonti, G. Finardi

Research output: Contribution to journalArticle

Abstract

The effects of two calcium channel blockers, nifedipine and tiapamil, on plasma lipoproteins were assessed in a double-blind study. After a two-week placebo period, 28 hypertensive outpatient subjects were randomly allocated to treatment with either nifedipine (10 to 20 mg TID) or tiapamil (300 to 600 mg BID) for six weeks. Both regimens were highly effective in lowering high blood pressure. Plasma lipid and lipoprotein levels did not change with nifedipine; however, high-density lipoprotein (HDL)-cholesterol (P <0.005), HDL2-cholesterol (P <0.05), and apoprotein A (P <0.02) all significantly increased in the tiapamil group. Both nifedipine and tiapamil add indifferent or even favorable effects on plasma lipoproteins to their antihypertensive efficacy, thus improving the overall cardiovascular risk in hypertensive subjects.

Original languageEnglish
Pages (from-to)720-725
Number of pages6
JournalCurrent Therapeutic Research
Volume45
Issue number5
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'High-density lipoprotein cholesterol increase in hypertensive patients treated with the calcium channel blocker tiapamil'. Together they form a unique fingerprint.

  • Cite this

    Perani, G., Muggia, C., Martignoni, A., Radaelli, A., Centeleghe, P., Passamonti, E., & Finardi, G. (1989). High-density lipoprotein cholesterol increase in hypertensive patients treated with the calcium channel blocker tiapamil. Current Therapeutic Research, 45(5), 720-725.